# Chronic Kidney Disease Market

> Chronic Kidney Disease Market Research Report Information by Diagnosis (Blood Test, Urine Test, Imaging Test, and Kidney Biopsy), by Treatment (Drugs, Dialysis, and Kidney Transplant) , by Indication (Type 1 Or Type 2 Diabetes, High Blood Pressure, and Polycystic Kidney Disease), by End User (Hospital & Clinics and Diagnostic Centers), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 5.6%
- **2025:** USD 90.47 Billion
- **2035:** USD 155.94 Billion
- **Key Players:** Fresenius Medical Care AG, Baxter International Inc., DaVita Inc., AstraZeneca plc, Bayer AG, Amgen Inc., Novartis AG, Boehringer Ingelheim

**Report ID:** MRFR/Pharma/4289-HCR · **Pages:** 110 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744

---

## Market Summary

The Global Chronic Kidney Disease Market size was valued at USD 40.53 Billion in 2024, and the market is projected to grow from USD 42.87 Billion in 2025 to USD 75.22 Billion by 2035, registering a CAGR of 5.78% during the forecast period 2025–2035. North America led the market in 2024 with over 45% share, generating around USD 18.24 Billion in revenue.
 
The Chronic Kidney Disease Market is primarily driven by the rapidly increasing global burden of diabetes, hypertension, and aging populations, which significantly raise the risk of kidney dysfunction. Growing awareness regarding early diagnosis and expanding access to advanced treatment options are further accelerating market expansion worldwide.
 
According to the Centers for Disease Control and Prevention, nearly 35.5 million U.S. adults are estimated to have chronic kidney disease, while diabetes and hypertension remain the leading contributors. Additionally, the World Health Organization highlights the growing global elderly population, expected to reach 1.4 billion people aged 60 years and above by 2030, increasing CKD treatment demand significantly.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising diabetes and hypertension prevalence | +1.30 pp | Global | Long-term (≥4 yr) | [1] |
| Cardio-renal pharmacotherapy label expansion | +1.05 pp | North America, Europe, Japan | Medium-term (2–4 yr) | [6] |
| Value-based kidney care payment models | +0.70 pp | North America | Medium-term (2–4 yr) | [3] |
| Demographic ageing of treated populations | +0.60 pp | Europe, Japan, China | Long-term (≥4 yr) | [2] |
| Home and decentralised dialysis expansion | +0.55 pp | Global | Medium-term (2–4 yr) | [17] |
| Emerging-market dialysis reimbursement | +0.50 pp | Asia-Pacific, MEA, South America | Long-term (≥4 yr) | [13] |
| AI-enabled early detection and screening | +0.40 pp | North America, Europe | Short-term (≤2 yr) | [9] |

### Diabetes and Hypertension Prevalence

Diabetes and hypertension account for about seven in ten occurrences of chronic kidney disease, and the International Diabetes Federation predicts that in 2024 there will be 589 million adults worldwide living with diabetes, which is expected to increase to 853 million by 2050 [[1]](https://diabetesatlas.org). That base isn’t cyclical. This translates to a predictable annual cohort acquiring stage 3 disease and precisely why the Chronic Kidney Disease Market has relatively low revenue volatility relative to other treatment categories. Payers have taken notice: the US Renal Data System reports that Medicare spends >USD130 billion per year on beneficiaries with kidney disease, an amount that makes upstream intervention financially rational rather than simply therapeutically desirable [[4]](https://usrds-adr.niddk.nih.gov).

### Cardio-Renal Pharmacotherapy

2021-2025 Dapagliflozin, empagliflozin and finerenone reset prescribing logic. The DAPA-CKD trial demonstrated a 39% reduction in the composite renal outcome, and FIGARO-DKD showed improvement in earlier albuminuria stages [[6]](https://nejm.org). Decline is currently controlled by nephrologists who earlier managed it. The revenue mix changes with renal protection drugs gaining share of expenditure and dialysis conversion rates softening. This replacement effect is built into the post-2031 CAGR slowdown illustrated in Section 3.

### Value-Based Kidney Care Models

CMS structured its Kidney Care Choices model to pay nephrology practices for keeping patients off dialysis, with transplant bonuses reaching USD 15,000 per beneficiary staged over three years [[3]](https://cms.gov). Roughly 130 participating entities covered several hundred thousand beneficiaries by 2025. Commercial payers copied the design. The practical consequence is a procurement shift toward diagnostics, remote monitoring, and care-navigation software rather than incremental dialysis chairs.

### Home and Decentralised Modalities

Baxter's Sharesource platform and Fresenius' connected cyclers now transmit treatment telemetry from tens of thousands of homes, and Japan's MHLW raised peritoneal dialysis reimbursement in its 2024 revision to lift home penetration above 5% [[17]](https://baxter.com)[[20]](https://mhlw.go.jp). Capital intensity falls, staffing per patient falls, and margin per treatment rises — three reasons operators keep funding the transition despite slower patient recruitment.

## Restraints

## Restraints Impact Analysis

Restraint attributions follow the same directional convention as Section 4. Each figure estimates suppressed growth in CAGR basis points; the values are analyst judgements, not additive subtractions from the headline rate for the Chronic Kidney Disease Market.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Dialysis nursing and technician shortages | −0.60 pp | North America, Europe | Short-term (≤2 yr) | [12] |
| Payer pressure on branded drug pricing | −0.50 pp | North America, Europe | Medium-term (2–4 yr) | [7] |
| Late-stage diagnosis and low screening uptake | −0.45 pp | Global | Long-term (≥4 yr) | [9] |
| Capital and reimbursement gaps in low-income markets | −0.40 pp | MEA, South America | Long-term (≥4 yr) | [2] |
| Transplant organ supply constraints | −0.30 pp | Global | Long-term (≥4 yr) | [5] |

### Workforce Scarcity in Dialysis Delivery

Clinics cannot run chairs they cannot staff. US dialysis operators reported technician turnover near 25% annually through 2023–2024, and several markets capped new shift openings rather than risk quality citations [[12]](https://mgma.com). Wage inflation of 6–8% compressed operator margins faster than reimbursement updates restored them. Automation helps at the margin, but a haemodialysis session still requires trained supervision, which puts a hard ceiling on volume growth in mature markets.

### Pricing Pressure on Branded Therapies

The Inflation Reduction Act placed multiple cardio-metabolic agents into Medicare price negotiation, with negotiated prices effective from 2026 and 2027 [[7]](https://ema.europa.eu). European biosimilar erythropoietin competition already cut anaemia-management pricing substantially. Volume in the Chronic Kidney Disease Market keeps rising; realised price per patient does not, which is why value forecasts grow slower than treated-population forecasts.

### Late Detection

The International Society of Nephrology's Global Kidney Health Atlas found that fewer than half of surveyed countries operate national screening programmes, and a large share of patients present within 90 days of needing renal replacement [[9]](https://theisn.org). Late presentation removes the entire pharmacotherapy revenue window and pushes patients directly into the costliest, least profitable emergency-start pathway.

## Opportunities

## Chronic Kidney Disease Market Opportunities

### Point-of-Care Biomarker Panels

Combining uACR with cystatin C and emerging tubular-injury markers compresses risk stratification from weeks to a single primary-care visit. Diagnostics remain the fastest-growing product line in the Chronic Kidney Disease Market at a 7.2% CAGR, and vendors that secure primary-care distribution rather than nephrology-only placement capture the larger volume pool.

### Algorithmic Risk Stratification as a Service

Health systems increasingly buy prediction, not software. Kidney-failure risk equations embedded into electronic health records and sold per-covered-life align neatly with capitated contracts [[3]](https://cms.gov). Vendors monetise longitudinal renal datasets through outcomes-linked pricing, a model already proven in cardiometabolic care.

### Emerging-Market Dialysis Networks

India's Pradhan Mantri National Dialysis Programme extended free haemodialysis across more than 1,500 district facilities, and Indonesia's JKN scheme now funds renal replacement for a large insured base [[13]](https://mohfw.gov.in). Asset-light franchise models — operator supplies machines and protocols, government supplies premises and staff — convert public budgets into recurring consumables revenue.

### Transplant-Adjacent Care

Organ perfusion technology, non-invasive rejection surveillance, and immunosuppression optimisation sit outside conventional dialysis economics but grow alongside them. UNOS recorded more than 27,000 US kidney transplants in 2023, an annual record [[5]](https://unos.org). Each transplant creates a decade of follow-up revenue for the Chronic Kidney Disease Market that dialysis operators rarely capture today.

### Rare Nephropathy Franchises

IgA nephropathy, C3 glomerulopathy, and Alport syndrome carry orphan designations, accelerated pathways, and premium pricing on small trial populations [[18]](https://kidney.org). Approvals for sparsentan and complement inhibitors validated the thesis, and several mid-cap developers now build entire pipelines around it.

## Future Outlook

## Chronic Kidney Disease Market Future Outlook

### Predictive Nephrology at Scale

By the early 2030s, risk scoring will run continuously rather than at annual review. Health systems already hold the inputs — creatinine trends, albuminuria, medication history — and the marginal cost of scoring is near zero. Growth in the Chronic Kidney Disease Market increasingly accrues to whoever owns the referral trigger, because detection timing determines which therapies a patient ever receives [[9]](https://theisn.org).

### Platform Economics in Dialysis

Device makers are becoming service platforms. Recurring consumables, connectivity subscriptions, and outcomes-linked contracts now generate a larger share of Fresenius and Baxter renal revenue than hardware sales [[16]](https://freseniusmedicalcare.com)[[17]](https://baxter.com). Expect installed-base defence, not machine innovation, to define competitive strategy through 2030.

### Decentralisation and the Clinic Footprint

Home penetration above 20% in major markets would strand a meaningful share of existing in-centre capacity. Operators are hedging by converting fixed clinics into hybrid training-and-support hubs, a model already piloted across Australia and the Nordics [[14]](https://oecd.org). Real-estate flexibility becomes a balance-sheet advantage.

### Equity, ESG, and Sustainable Dialysis

Each haemodialysis session consumes roughly 300–500 litres of water, and large operators now report renal-specific water and carbon intensity in sustainability disclosures [[23]](https://kdigo.org). Tender scoring in Europe increasingly weights environmental performance. Sustainability moves from reporting obligation to procurement criterion in the Chronic Kidney Disease Market, favouring vendors with water-recycling and low-power cycler designs.

## Segment Insights

## Chronic Kidney Disease Market Segmentation

Segmentation in the Chronic Kidney Disease Market follows product type, end user, and geography, with each dimension disclosing a single headline metric below.

### By Product Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Treatment | 69.7% revenue share (2025) | Dialysis consumables, pharmacotherapy, transplant support |
| Diagnosis | 7.2% CAGR (2026–2035) | Biomarker panels, imaging, AI-based risk stratification |

Treatment dominates because renal replacement is continuous, expensive, and non-discretionary — a single haemodialysis patient consumes over 150 treatments annually. Diagnosis grows faster from a smaller base as payers fund detection they previously ignored. The gap between the two segments narrows through the 2030s but does not close, and the Chronic Kidney Disease Market stays treatment-weighted throughout the study period.

### By End User

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 40.1% revenue share (2025) | Acute kidney injury, comorbidity management, transplant surgery |
| Dialysis Centres | 6.5% CAGR (2026–2035) | Outpatient capacity expansion and operator consolidation |
| Homecare Settings | USD 12.40 Billion (2025) | Peritoneal dialysis and connected home haemodialysis |
| Other End Users | 4.1% CAGR (2026–2035) | Ambulatory clinics, research institutions, long-term care |

Hospitals retain the largest share of the Chronic Kidney Disease Market because advanced kidney disease rarely travels alone; cardiovascular events, infection, and metabolic crises route patients back to inpatient settings regardless of where routine dialysis happens. Dialysis centres nonetheless outgrow hospitals as tariff structures reward outpatient delivery, and homecare quietly compounds as kidney disease management drugs and remote monitoring reduce the clinical case for supervised sessions.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.3% revenue share | Value-based nephrology, home dialysis, precision therapeutics |
| Europe | USD 24.25 Billion | Universal screening, biosimilar adoption, cross-border HTA |
| Asia-Pacific | 7.5% CAGR (2026–2035) | Public dialysis networks, domestic device manufacturing |
| South America | 5.4% revenue share | Private clinic consolidation, public tender supply |
| Middle East & Africa | USD 3.51 Billion | Sovereign health investment, transplant infrastructure |
| Total | USD 90.47 Billion | — |

Regional performance in the Chronic Kidney Disease Market splits along reimbursement maturity rather than disease prevalence. Wealthy markets monetise each patient heavily; high-burden markets monetise volume.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 84.5% of regional revenue | Medicare ESRD entitlement and Kidney Care Choices |
| Canada | USD 3.10 Billion (2025) | Provincial home-dialysis targets |
| Mexico | 6.8% CAGR (2026–2035) | IMSS coverage expansion for renal replacement |

The US remains the single most valuable geography in the Chronic Kidney Disease Market because Medicare covers end-stage [renal disease](https://www.marketresearchfuture.com/reports/renal-disease-market-3167) irrespective of age, creating a guaranteed payer for roughly 800,000 treated patients [[4]](https://usrds-adr.niddk.nih.gov). Canada's provincial systems push home modalities harder than any comparable jurisdiction, with British Columbia and Ontario exceeding 25% home penetration. Mexico's growth comes from a lower base as IMSS and IMSS-Bienestar absorb previously out-of-pocket dialysis demand.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 22.4% of regional revenue | Dense clinic network, statutory insurance coverage |
| UK | USD 3.36 Billion (2025) | NHS Renal Services Transformation Programme |
| France | 14.9% of regional revenue | REIN registry-driven care planning |
| Italy | USD 2.55 Billion (2025) | Regional dialysis procurement consolidation |
| Spain | 8.1% of regional revenue | Highest transplant rate globally |
| Nordic Countries | 5.2% CAGR (2026–2035) | Early screening and primary-care integration |
| Russia | USD 1.62 Billion (2025) | State dialysis programme expansion |
| Rest of Europe | 4.6% CAGR (2026–2035) | CEE capacity catch-up |

Europe's economics differ from North America's: statutory tariffs cap per-treatment revenue, so growth comes from earlier detection and drug mix rather than volume. Spain's ONT transplant model, running above 50 deceased donors per million population, structurally reduces dialysis years per patient while expanding follow-up care spend [[8]](https://era-online.org)[[14]](https://oecd.org).

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 31.8% of regional revenue | Urban resident insurance dialysis coverage |
| India | 8.9% CAGR (2026–2035) | Pradhan Mantri National Dialysis Programme |
| Japan | USD 5.12 Billion (2025) | World's highest dialysis prevalence per capita |
| South Korea | 7.4% of regional revenue | NHIS reimbursement and clinic density |
| ASEAN | 8.2% CAGR (2026–2035) | Indonesia JKN and Vietnam social insurance |
| Rest of Asia-Pacific | USD 2.18 Billion (2025) | Australia and New Zealand home dialysis leadership |

Asia-Pacific supplies the growth engine of the Chronic Kidney Disease Market. China treats over one million dialysis patients with penetration still well below need, and domestic manufacturers such as SWS Hemodialysis Care and Weigao have driven equipment prices down sharply, expanding affordable capacity [[13]](https://mohfw.gov.in)[[21]](https://nhc.gov.cn). India's programme model — public premises, private operators, per-session tariffs — has become the reference template for other low-cost markets.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 52.6% of regional revenue | SUS universal dialysis funding |
| Argentina | USD 0.71 Billion (2025) | PAMI and provincial coverage |
| Rest of South America | 5.9% CAGR (2026–2035) | Chile and Colombia clinic expansion |

Brazil's SUS funds the overwhelming majority of the region's dialysis sessions through nationally set tariffs, which makes operator profitability a direct function of federal budget revisions [[19]](https://gov.br/saude). Consolidation continues as smaller independent clinics sell into regional chains seeking procurement scale.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 24.8% of regional revenue | Vision 2030 health sector transformation |
| UAE | USD 0.44 Billion (2025) | Mandatory insurance and medical tourism |
| South Africa | 6.1% CAGR (2026–2035) | Private sector dialysis growth |
| Egypt | 13.2% of regional revenue | High hepatitis-related renal burden |
| Rest of MEA | USD 0.85 Billion (2025) | Gulf sovereign health investment |

Gulf states invest ahead of demand. Saudi Arabia's Health Sector Transformation Programme funds new nephrology centres and transplant capability as part of a broader privatisation push. At the same time, Egypt's burden reflects decades of hepatitis C sequelae now presenting as renal failure [[22]](https://vision2030.gov.sa). Sub-Saharan access remains the sharpest global inequity, with treated prevalence a small fraction of estimated need.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration in the Chronic Kidney Disease Market is high by healthcare standards. Estimated HHI sits in the 1,450–1,650 band, with the top five participants controlling roughly 34–38% of global revenue. Vertical integration explains much of it: Fresenius manufactures machines, operates clinics, and supplies dialysate, while DaVita's scale gives it procurement leverage few independents match. Pharmaceutical participants compete on a different axis entirely, chasing earlier-stage patients that dialysis operators never see.

| Company | Est. Revenue Share Range | Key Offerings for Chronic Kidney Disease Market | Strategic Positioning |
| --- | --- | --- | --- |
| Fresenius Medical Care AG | ~9–12% | Dialysis machines, dialysers, clinic network, connected care | Vertically integrated global leader |
| Baxter International Inc. | ~6–8% | Peritoneal dialysis systems, Sharesource platform, HD solutions | Home modality and connectivity specialist |
| DaVita Inc. | ~5–7% | Outpatient and home dialysis services, integrated kidney care | US services scale player |
| AstraZeneca plc | ~5–7% | Dapagliflozin, roxadustat, cardio-renal portfolio | Pharmacotherapy category creator |
| Bayer AG | ~4–6% | Finerenone, cardio-renal pipeline | Non-steroidal MRA franchise leader |
| Amgen Inc. | ~3–5% | Anaemia and mineral bone disorder therapeutics | Established nephrology biologics base |
| Novartis AG | ~3–5% | Iptacopan, rare nephropathy pipeline | Complement and rare disease focus |
| Boehringer Ingelheim | ~3–4% | Empagliflozin renal indications | Cardio-renal-metabolic co-marketing |
| CSL Vifor | ~2–4% | Iron therapies, phosphate binders, sparsentan | Renal-dedicated specialty portfolio |
| Otsuka Pharmaceutical | ~2–3% | Tolvaptan for polycystic kidney disease | Rare renal indication leadership |
| GSK plc | ~1–3% | Daprodustat, anaemia management | HIF-PHI segment entrant |
| Akebia Therapeutics | ~1–2% | Vadadustat, phosphate management | Focused mid-cap nephrology developer |

## Recent News & Developments

## Recent News & Developments

- Novartis (March 2024): Received FDA accelerated approval for iptacopan in paroxysmal nocturnal haemoglobinuria and advanced filings in IgA nephropathy, opening a complement-driven revenue line in rare renal disease [[10]](https://fda.gov).
- CSL Vifor and Travere (2023): Sparsentan gained accelerated approval for IgA nephropathy, validating premium pricing on orphan nephropathies and drawing new developer entrants [[18]](https://kidney.org).
- CMS (January 2024): Expanded the Kidney Care Choices model into additional performance years with revised transplant bonus structures, deepening incentives to delay dialysis initiation [[3]](https://cms.gov).
- Bayer (2024): Reported finerenone crossing blockbuster trajectory in cardio-renal indications following broadened European reimbursement across major markets [[6]](https://nejm.org).
- Fresenius Medical Care (2024): Completed a multi-year operating model overhaul, divesting non-core assets and concentrating capital on care delivery and connected products [[16]](https://freseniusmedicalcare.com).
- Baxter (2025): Extended remote peritoneal dialysis management across additional Asia-Pacific markets, targeting home penetration gains in Japan and Australia [[17]](https://baxter.com).
- AstraZeneca (2025): Announced expanded real-world evidence collaborations on dapagliflozin renal outcomes with several national registries, supporting earlier-stage prescribing [[6]](https://nejm.org).
- Government of India (2024): Broadened the national dialysis programme's district coverage and added peritoneal dialysis provisioning to the scheme [[13]](https://mohfw.gov.in).

## Frequently Asked Questions

**Q: What should procurement teams evaluate when selecting a dialysis equipment vendor?**
A: Prioritise service-network density, consumables contract terms, and remote-monitoring interoperability over headline machine price. Seven-year total cost of ownership typically exceeds acquisition cost several times over, and consumables lock-in drives most of that gap [12].

**Q: How does the Chronic Kidney Disease Market absorb biosimilar erythropoietin competition?**
A: Biosimilar erythropoiesis-stimulating agents have compressed anaemia-management pricing sharply across Europe since 2019. Suppliers now compete on bundled anaemia and iron-management protocols rather than molecule price alone [7].

**Q: Which regulatory nuance most affects new entrants to the Chronic Kidney Disease Market in Europe?**
A: EU Regulation 2021/2282 introduced joint clinical assessments, phasing across therapeutic areas through 2030. Nephrology entrants should build comparative-effectiveness dossiers before national pricing negotiations begin [15].

**Q: Are AI-based kidney risk stratification tools reimbursable today?**
A: Coverage remains inconsistent. US Medicare funds a narrow set of algorithm-driven services through emerging code pathways, while most European systems pay for them only inside integrated or capitated care contracts [11].

**Q: What integration challenge slows home dialysis adoption most?**
A: Connectivity. Cyclers must write treatment logs into electronic health records without manual re-entry, and many legacy nephrology systems still lack modern interoperability endpoints, forcing expensive middleware builds [11].

**Q: How does the Chronic Kidney Disease Market treat pediatric and rare nephropathy niches?**
A: Orphan designations for IgA nephropathy and C3 glomerulopathy allow smaller trials and premium pricing. These indications now attract venture funding disproportionate to their patient volume [18].

**Q: What is the biggest investment risk for private dialysis operators?**
A: Reimbursement concentration. Where one public payer sets tariffs for most treatments, a single budget revision can reset operator margins within a fiscal year, as Brazilian and Indian operators have experienced [19].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/chronic-kidney-disease-market-5744*